I have had my doubts about the relationship between NP and

New Post Public Reply Private Reply Replies (1) Message Board
TechGuru
869
I have had my doubts about the relationship between NP and BP. Not sure what has transpired but I have "felt" NP a bit cold towards BP. In last conference call he mentioned that "we don't count on Dr. Patterson paper" or something similar. Don't remember the exact words.

Listening to Dr. Patterson interview yesterday it is obvious that he is fully in our side and remains the best Leronlimab advocate. So, I am not sure now that something has gone wrong as Dr. Paterson is talking as he was and is the biggest fan of CytyDyn.

His paper is coming !!!!! Below a transcript (from Dr. Yo's interview) where he explains what is going on:

What is going on with paper: Again I, I’m frustrated by the Journal it up the COVID endemic forcing people to publish preprints; because people who don’t understand the publication process know that it’s a relatively long process, is obvious accelerated in COVID and, and clearly you know, there was, there is several issues, I mean the main being no controls, right? and you know, these patients beyond critical and we are blessed that hum … some of the other coauthors and myself had great collaborators who stepped up the plate and said: listen I got some critical controls that haven’t been treated and let’s ad add those to the paper.
and then, you know, by the time we add those we had day 14th data which made everything even more powerful like I said this inverse correlation between CD8s coming back up and plasma viral load going down, absolutely critical, now people are coming out in reverse saying that is the CD8 deficiency ah, or the recovery of the CD8s ahmm that is eventually, you know, going to eliminate a virally infected cells. So then, we included CD 14th day and then, of course, it was outcomes: you know all 11 patients had incredible immunologic response the outcomes were good for this particular population, 8 out of eleven, or 7 out of 11 were transplant patients on top of everything else .. ah I just had not been addressed … So in fact, I checked on it today and it's, it's in process I think they are probably close to a decision, and then the journals when there is a decision will get it out in e-pub relatively quickly. But if you talk about the time from submission to going out in e-Pub in 3 months I mean, under normal circumstances, we would be popping the champagne bottle in how fast that is, right ??? some publications normally take 6, 12 months from the time they are actually submitted to the time they are out in print. so you know, I get the frustration, I’m just a frustrated at the pace, but you know what ? after publishing 150 papers, nothing, this is business as usual. Are the political things going behind the scenes? possibly ahh. But, in the day is gonna come out; I mean, the bottom line is: you don’t write a great paper and doesn’t get out anywhere is only matter of which journal gets it out there … at the end of the day, it does not matter, right??? if it is in a top tier Journal it's fine but it doesn't have to be, you know, solely New England Journal, Lancet, Nature, Science, you know, I published in all those before and yes, is a great honor but you know what ? they accept one in 100 papers so … yeah there’s other papers on Leronlimab that have undergone the same fate, so, we are in the same boat and I think the recurring theme is: lack of control patients and, obviously, that is going to come in the clinical trials and certainly in the IND’s we didn’t have controls, we didn’t have placebo controls, we went out and got them from our obviously some great collaborators of ours which made the trial much more than just, you know, just, looking at Leronlimab, we had to look at what was going on and repeat the entire assays that we did on the treated patients on the controls, so you can imagine the study size actually double, you know, in the course of, this being evaluated, so again, yeah there’s every reason in the world why, you know, it’s taking this long, but like I said, with, after 150 publications there is nothing that is unusual about this in the least


I can't wait to see the final paper, and more so, the "market" and scientific community reaction to it.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JobPlanner Boosts Tools to Shield Margins in Construction

Updated Category News Views 94

Real-Time Solutions for Real-World Challenges JobPlanner is stepping up its game with some beefed-up financial management tools, and I gotta admit, it's like a lifeline in the raging sea of construction costs. We're talking about a souped-up Real-Time Job Costing Suite tailored for general and specialty contractors who are tired of watching their profits evaporate into...

Continue Reading
Illumina's Role in Singapore's Precision Medicine Leap

Updated Category News Views 79

Singapore's Bold Step into Precision Medicine When it comes to revolutionizing healthcare, Singapore isn't content to sit on the sidelines. They've just thrown a serious hat into the ring with the SG-INSIGHT study, a cornerstone of their National Precision Medicine programme. And Illumina, Inc. (NASDAQ:ILMN) is right there in it, gearing up to sequence the genomes of...

Continue Reading
Protalix to Reveal Q3 2026 Results Amid Rare Disease Push

Updated Category News Views 0

Looking Ahead to Protalix's Q3 Revelation Nobody's pretending it's a cakewalk to stay ahead in the biopharma sector, especially when you're tangoing with the unpredictable world of rare disease therapeutics. But here we are, with Protalix BioTherapeutics scheduling their third-quarter financial results announcement for November 10, 2026. If you've been tracking them—or...

Continue Reading
Edible Oils: Market Growth, Trends, and Investments

Updated Category News Views 0

Riding the Edible Oil Wave The edible oils market seems to be gearing up for a steady rise. Folks, the numbers are speaking loud and clear. We're looking at the market booming from USD 277.74 billion in 2026 to a hefty USD 351.08 billion in 2031. According to MarketsandMarkets™, a compound annual growth rate (CAGR) of 4.8% is on the cards. Now, if that doesn't get the...

Continue Reading
Teamsters Strike: Chicago Parking Dispute Unfolds

Updated Category News Views 0

Union Rumble: Parking Showdown in Chicago In the windy streets of Chicago, nearly 1,200 members of Teamsters Local 727 are striking, and folks, it's not just about parking cars. These workers have thrown down the gauntlet against parking operators throughout Chicagoland. They're not just peeved with a bad offer—they're downright firing back at labor law violations,...

Continue Reading
NABEP Powers Ahead with Orinoco Furnace Restart

Updated Category News Views 49

Revving Up the Engines in the Orinoco Belt And HERE we are again, ringing the bell on another bold move in the world of energy. NABEP is pulling back the curtain on their revamped activities in the Orinoco Belt. You're telling me they just fired up one heck of a furnace? In this relentless pursuit to spike their output, you've gotta respect the hustle. It's like cranking...

Continue Reading
Syra Health Hits Record Revenue, Sustains Growth

Updated Category News Views 0

Syra Health Reports Stellar Q3 Performance Folks, let's dive right into the figures: Syra Health's Q3 2026 performance is nothing short of a powerhouse display. We're talking about a jaw-dropping 52% surge in revenue compared to the same period last year, climbing to a record $2.6 million. It's not often you see a company swing its EPS from a loss of $(0.02) to a positive...

Continue Reading
New Xavier Ochsner College of Medicine Opens Applications

Updated Category News Views 12

Paving New Paths in Medical Education Out of the vibrant hub of New Orleans comes a fresh twist in the world of medical education: the Xavier Ochsner College of Medicine is now taking applications for its 2027 debut class. The key here is a powerhouse collaboration between Xavier University of Louisiana and Ochsner Health. These are big names in their own right,...

Continue Reading
UFC Gym Expands, Opening Murfreesboro Location Soon

Updated Category News Views 137

UFC GYM Targets the Heart of Murfreesboro They're doing it again—UFC GYM's tossing another gym into the mix, folks! This time, it's Murfreesboro, Tennessee, catching the brand's punchy, high-energy splash. Don't mistake this for just another big-box, bench-press-jamboree. Their doors swing open come November 14, and this ain't some punk move. We're talking a whopping...

Continue Reading
Reju Partners with Six Mills to Advance Textile Regeneration

Updated Category News Views 86

Big Moves in Textile Regeneration Now here's a move that's got the fabric world buzzing: Reju, the scrappy textile-to-textile regenerative powerhouse, is teaming up with six mills spread across Europe and the U.S. They’re setting the stage to crank up their polyester recycling game and flood the market with sustainable, eco-friendly fabrics. It's a bold step toward...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Solutions and Investment Strategies from Aiden Labs

Updated Category News Views 502

Transforming Investment Strategies with Aiden Labs Aiden Labs is paving the way for the future of cryptocurrency investments through its innovative platform that seamlessly integrates artificial intelligence (AI) with decentralized finance (DeFi) solutions. The introduction of the DeFAI-agent marks a significant milestone, as it redefines the investment landscape by...

Continue Reading
Class Action Lawsuit Filed Against Five Below, Inc. (NASDAQ: FIVE)

Updated Category News Views 97

Class Action Lawsuit Filed Against Five Below, Inc. Pomerantz LLP has launched a class action lawsuit against Five Below, Inc. (NASDAQ: FIVE), addressing serious allegations of securities fraud and potentially illegal business practices involving the company and certain executives. This announcement has generated considerable interest among investors and shareholders...

Continue Reading
Terry Dunlap Joins NetRise to Elevate Cybersecurity Strategy

Updated Category News Views 170

Terry Dunlap Joins NetRise to Strengthen Cybersecurity Strategy Terry Dunlap, a highly regarded expert in the cybersecurity field, is stepping into a key position at NetRise as the Senior Vice President of Corporate Strategy and Development. In this innovative role, Dunlap will lead the company through its next major growth phase, with a focus on addressing the...

Continue Reading
Historic Treaty Settlement for Kiashke Zaaging Anishinaabek

Updated Category News Views 391

Kiashke Zaaging Anishinaabek and Canada Reach a Landmark Agreement Honouring treaty relationships is crucial in furthering reconciliation and rebuilding trust between Indigenous communities and the Canadian government. Recently, Chief Wilfred King of Kiashke Zaaging Anishinaabek announced a significant agreement alongside Minister Gary Anandasangaree, responsible for...

Continue Reading
YieldMax™ ETFs Unveils Latest Distribution Details for Investors

Updated Category News Views 789

Recent Distribution Announcements from YieldMax™ ETFs YieldMax™ is making waves in the investment world with its recent announcement regarding distributions for its lineup of ETFs. These distributions are essential for investors seeking to maximize their income streams through strategically managed funds. Overview of YieldMax™ ETFs YieldMax™ ETFs are designed to...

Continue Reading